Revance Therapeutics, Inc. (RVNC)

Number of records: 50
SEC FilingInsiderCompanyTrade DateTransactionSharesAvg. PriceTotal% HoldingsReturn
30-Jul-21 8:57 PM
View: 
Rankin Aubrey
President, Innovation & Tech
Director
Revance Therapeutics, Inc. (RVNC) 28-Jul-21Market Sale (Planned) 34,332$30.00$1,029,960.00(6%)
590.02K to 555.69K
3%
30-Jul-21 8:57 PM
View: 
Rankin Aubrey
President, Innovation & Tech
Director
Revance Therapeutics, Inc. (RVNC) 28-Jul-21Market Sale 20,000$30.15$603,000.00(3%)
610.02K to 590.02K
3%
28-Jul-21 9:48 PM
View: 
Rankin Aubrey
President, Innovation & Tech
Director
Revance Therapeutics, Inc. (RVNC) 26-Jul-21Market Sale (Planned) 55,382$29.72$1,645,950.00(8%)
665.4K to 610.02K
3%
02-Jul-21 7:56 PM
View: 
Sjuts Dustin S
Chief Commercial Officer
Revance Therapeutics, Inc. (RVNC) 30-Jun-21Acquisition (other) 882$24.09$21,246.501%
65.1K to 65.98K
02-Jul-21 7:52 PM
View: 
Foley Mark J
CEO & President
Director
Revance Therapeutics, Inc. (RVNC) 30-Jun-21Acquisition (other) 882$24.09$21,246.50< 1%
881.19K to 882.07K
02-Jul-21 7:53 PM
View: 
Schilke Tobin
CFO
Revance Therapeutics, Inc. (RVNC) 30-Jun-21Acquisition (other) 446$24.09$10,743.70< 1%
68.76K to 69.21K
07-May-21 7:23 PM
View: 
Ware Olivia C
Director
Revance Therapeutics, Inc. (RVNC) 05-May-21Grant 674----11%
6.41K to 7.08K
07-May-21 7:06 PM
View: 
Gangolli Julian S
Director
Revance Therapeutics, Inc. (RVNC) 05-May-21Grant 4,013----24%
16.5K to 20.51K
07-May-21 7:08 PM
View: 
Kolaja Carey Oconnor
Director
Revance Therapeutics, Inc. (RVNC) 05-May-21Grant 674----11%
6.29K to 6.97K
07-May-21 7:15 PM
View: 
Vickers Philip J.
Director
Revance Therapeutics, Inc. (RVNC) 05-May-21Grant 4,013----20%
19.65K to 23.66K
07-May-21 7:04 PM
View: 
Beraud Jill
Director
Revance Therapeutics, Inc. (RVNC) 05-May-21Grant 4,013----27%
15.0K to 19.01K
07-May-21 7:10 PM
View: 
Nolet Chris
Director
Revance Therapeutics, Inc. (RVNC) 05-May-21Grant 4,013----27%
15.0K to 19.01K
07-May-21 7:12 PM
View: 
Russell Angus C.
Director
Revance Therapeutics, Inc. (RVNC) 05-May-21Grant 4,013----24%
16.5K to 20.51K
16-Apr-21 10:00 PM
View: 
Sjuts Dustin S
Chief Commercial Officer
Revance Therapeutics, Inc. (RVNC) 15-Apr-21Payment of Exercise 411$28.16$11,573.80(< 1%)
65.51K to 65.1K
0%
06-Apr-21 7:41 PM
View: 
Rankin Aubrey
President, Innovation & Tech
Director
Revance Therapeutics, Inc. (RVNC) 05-Apr-21Market Sale (Planned) 2$28.28$56.56(< 1%)
665.4K to 665.4K
(< 1%)
17-Mar-21 7:29 PM
View: 
Moxie Dwight
SVP, GC & Secretary
Revance Therapeutics, Inc. (RVNC) 15-Mar-21Payment of Exercise 2,881$27.73$79,890.10(6%)
52.36K to 49.48K
(< 1%)
17-Mar-21 7:27 PM
View: 
Joshi Abhay
COO, President, R&D
Revance Therapeutics, Inc. (RVNC) 15-Mar-21Payment of Exercise 1,354$27.73$37,546.40(1%)
129.72K to 128.37K
(< 1%)
10-Mar-21 7:13 PM
View: 
Ware Olivia C
Director
Revance Therapeutics, Inc. (RVNC) 08-Mar-21Grant 6,408----100%
0 to 6.41K
05-Mar-21 8:10 PM
View: 
Rankin Aubrey
President, Innovation & Tech
Director
Revance Therapeutics, Inc. (RVNC) 04-Mar-21Market Sale (Planned) 33,119$25.43$842,216.00(5%)
698.52K to 665.4K
(1%)
02-Mar-21 8:17 PM
View: 
Kolaja Carey Oconnor
Director
Revance Therapeutics, Inc. (RVNC) 01-Mar-21Grant 6,294----100%
0 to 6.29K
19-Feb-21 8:13 PM
View: 
Sjuts Dustin S
Chief Commercial Officer
Revance Therapeutics, Inc. (RVNC) 15-Feb-21Payment of Exercise 2,410$28.97$69,817.70(4%)
67.92K to 65.51K
3%
19-Feb-21 8:15 PM
View: 
Schilke Tobin
CFO
Revance Therapeutics, Inc. (RVNC) 15-Feb-21Payment of Exercise 2,657$28.97$76,973.30(4%)
71.42K to 68.76K
3%
19-Feb-21 8:10 PM
View: 
Joshi Abhay
COO, President, R&D
Revance Therapeutics, Inc. (RVNC) 15-Feb-21Payment of Exercise 4,848$28.97$140,447.00(4%)
134.57K to 129.72K
3%
04-Feb-21 9:16 PM
View: 
Rankin Aubrey
President, Innovation & Tech
Director
Revance Therapeutics, Inc. (RVNC) 02-Feb-21Grant 11,905----2%
686.62K to 698.52K
04-Feb-21 9:15 PM
View: 
Schilke Tobin
CFO
Revance Therapeutics, Inc. (RVNC) 02-Feb-21Grant 22,620----46%
48.8K to 71.42K
04-Feb-21 9:16 PM
View: 
Joshi Abhay
COO, President, R&D
Revance Therapeutics, Inc. (RVNC) 02-Feb-21Grant 22,620----20%
111.95K to 134.57K
04-Feb-21 9:12 PM
View: 
Moxie Dwight
SVP, GC & Secretary
Revance Therapeutics, Inc. (RVNC) 02-Feb-21Grant 19,346----59%
33.01K to 52.36K
04-Feb-21 9:10 PM
View: 
Foley Mark J
CEO & President
Director
Revance Therapeutics, Inc. (RVNC) 02-Feb-21Grant 40,715----5%
840.48K to 881.19K
04-Feb-21 9:16 PM
View: 
Sjuts Dustin S
Chief Commercial Officer
Revance Therapeutics, Inc. (RVNC) 02-Feb-21Grant 22,620----50%
45.3K to 67.92K
03-Feb-21 8:13 PM
View: 
Rankin Aubrey
President, Innovation & Tech
Director
Revance Therapeutics, Inc. (RVNC) 01-Feb-21Market Sale (Planned) 33,119$25.95$859,438.00(5%)
719.74K to 686.62K
(8%)
04-Jan-21 7:59 PM
View: 
Sjuts Dustin S
Chief Commercial Officer
Revance Therapeutics, Inc. (RVNC) 31-Dec-20Acquisition (other) 348$21.36$7,433.45< 1%
44.95K to 45.3K
04-Jan-21 8:02 PM
View: 
Schilke Tobin
CFO
Revance Therapeutics, Inc. (RVNC) 31-Dec-20Acquisition (other) 493$21.36$10,530.701%
48.31K to 48.8K
04-Jan-21 8:01 PM
View: 
Rankin Aubrey
President, Innovation & Tech
Director
Revance Therapeutics, Inc. (RVNC) 30-Dec-20Market Sale (Planned) 33,119$27.82$921,212.00(4%)
752.86K to 719.74K
(2%)
22-Dec-20 8:37 PM
View: 
Sjuts Dustin S
Chief Commercial Officer
Revance Therapeutics, Inc. (RVNC) 15-Dec-20Payment of Exercise 562$26.75$15,033.50(1%)
45.51K to 44.95K
(3%)
22-Dec-20 8:39 PM
View: 
Schilke Tobin
CFO
Revance Therapeutics, Inc. (RVNC) 15-Dec-20Payment of Exercise 1,556$26.75$41,623.00(3%)
49.86K to 48.31K
(3%)
02-Dec-20 8:55 PM
View: 
Rankin Aubrey
President, Innovation & Tech
Director
Revance Therapeutics, Inc. (RVNC) 30-Nov-20Market Sale (Planned) 33,119$23.85$789,888.00(4%)
785.98K to 752.86K
(16%)
30-Oct-20 8:24 PM
View: 
Rankin Aubrey
President, Innovation & Tech
Director
Revance Therapeutics, Inc. (RVNC) 29-Oct-20Market Sale (Planned) 33,119$26.15$865,949.00(4%)
819.1K to 785.98K
(5%)
15-Oct-20 6:57 PM
View: 
Foley Mark J
CEO & President
Director
Revance Therapeutics, Inc. (RVNC) 13-Oct-20Payment of Exercise 66,106$27.62$1,825,850.00(7%)
906.58K to 840.48K
< 1%
02-Oct-20 8:30 PM
View: 
Moxie Dwight
SVP, GC & Secretary
Revance Therapeutics, Inc. (RVNC) 30-Sep-20Payment of Exercise 4,236$25.14$106,493.00(11%)
37.25K to 33.01K
(10%)
02-Oct-20 8:32 PM
View: 
Schilke Tobin
CFO
Revance Therapeutics, Inc. (RVNC) 30-Sep-20Payment of Exercise 5,446$25.14$136,912.00(10%)
55.31K to 49.86K
(10%)
02-Oct-20 8:34 PM
View: 
Sjuts Dustin S
Chief Commercial Officer
Revance Therapeutics, Inc. (RVNC) 30-Sep-20Grant 17,500----51%
34.06K to 51.56K
02-Oct-20 8:31 PM
View: 
Joshi Abhay
COO, President, R&D
Revance Therapeutics, Inc. (RVNC) 30-Sep-20Grant 17,500----17%
101.83K to 119.33K
02-Oct-20 8:34 PM
View: 
Sjuts Dustin S
Chief Commercial Officer
Revance Therapeutics, Inc. (RVNC) 30-Sep-20Payment of Exercise 6,051$25.14$152,122.00(12%)
51.56K to 45.51K
(10%)
02-Oct-20 8:30 PM
View: 
Moxie Dwight
SVP, GC & Secretary
Revance Therapeutics, Inc. (RVNC) 30-Sep-20Grant 12,250----49%
25.0K to 37.25K
02-Oct-20 8:33 PM
View: 
Foley Mark J
CEO & President
Director
Revance Therapeutics, Inc. (RVNC) 30-Sep-20Grant 301,000----69%
433.5K to 734.5K
02-Oct-20 8:33 PM
View: 
Foley Mark J
CEO & President
Director
Revance Therapeutics, Inc. (RVNC) 30-Sep-20Payment of Exercise 143,269$25.14$3,601,780.00(20%)
734.5K to 591.23K
(10%)
02-Oct-20 8:32 PM
View: 
Schilke Tobin
CFO
Revance Therapeutics, Inc. (RVNC) 30-Sep-20Grant 15,750----40%
39.56K to 55.31K
02-Oct-20 8:31 PM
View: 
Joshi Abhay
COO, President, R&D
Revance Therapeutics, Inc. (RVNC) 30-Sep-20Payment of Exercise 7,382$25.14$185,583.00(6%)
119.33K to 111.95K
(10%)
30-Sep-20 9:21 PM
View: 
Rankin Aubrey
President, Innovation & Tech
Director
Revance Therapeutics, Inc. (RVNC) 28-Sep-20Market Sale (Planned) 33,119$26.18$867,055.00(4%)
852.21K to 819.1K
(5%)
15-Oct-20 6:57 PM
View: 
Foley Mark J
CEO & President
Director
Revance Therapeutics, Inc. (RVNC) 23-Jul-20Grant 264,439----45%
591.23K to 855.67K